Table 6 Summary of consensus recommendations
From: Expert consensus on the monitoring and treatment of sepsis-induced immunosuppression
Consensus | Consistency evaluation and recommendation |
|---|---|
Patients with sepsis had immunosuppression | |
 Presence of innate immunosuppression | Very good consistency, strong recommendation |
 Presence of acquired immunosuppression | Very good consistency, strong recommendation |
Sepsis-related immune function monitoring | |
 Initiated immune monitoring within 48 h after diagnosis of sepsis | Very good consistency, strong recommendation |
 Need for dynamic monitoring of immune status | Very good consistency, strong recommendation |
Patients with sepsis had high risk factors for immunosuppression | |
 Elderly (age ≥ 65 years old) | Very good consistency, strong recommendation |
 Patients with malignant tumors under radiotherapy/chemotherapy within 3 months | Perfect consistency, strong recommendation |
 Patients undergoing long-term immunosuppressive or steroids therapy | Perfect consistency, strong recommendation |
 Malnutrition (BMI < 18.5 kg/m2) | Good consistency, weak recommendation |
 Secondary infection | Good consistency, weak recommendation |
Monitoring indicators for immunosuppression in patients with sepsis | |
 Decreased mHLA-DR | Very good consistency, strong recommendation |
 Reduced responsiveness of monocytes to endotoxin stimulation | Very good consistency, strong recommendation |
 Decreased peripheral blood lymphocyte count | Very good consistency, strong recommendation |
 Increased regulatory T cell ratio | Very good consistency, strong recommendation |
 Th1/Th2 balance disorder | Good consistency, weak recommendation |
 Decreased peripheral blood immunoglobulin (IgA, IgM and IgG) concentrations | Good consistency, weak recommendation |
Immunomodulatory therapy for sepsis | |
 mHLA-DR < 15,000 AB/C or percentage of mHLA-DR < 60% | Good consistency, weak recommendation |
 Total lymphocytes < 1.1 × 109/L | Good consistency, weak recommendation |
 Presence of risk factors for immunosuppression | Good consistency, weak recommendation |
Immunomodulatory drugs | |
 IgG | Good consistency, no recommendation |
 Recombinant GM-CSF | Very good consistency, no recommendation |
 Tα1 | Good consistency, weak recommendation |
Immunomodulatory therapy required dynamic monitoring of immune function | Very good consistency, strong recommendation |
Endpoint of immunomodulatory therapy | |
 mHLA-DR ≥ 15,000 AB/C or percentage of mHLA-DR ≥ 60% | Good consistency, weak recommendation |
 Total lymphocytes ≥ 1.1 × 109/L | Very good consistency, strong recommendation |